Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

ATAI Life Sciences BV

Current price
1.66 USD -0.02 USD (-1.19%)
Last closed 1.61 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 269 523 648 USD
Yield for 12 month -7.26 %
21.11.2021 - 28.11.2021

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London. Address: Wallstrasse 16, Berlin, Germany, 10179

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

10.68 USD

P/E ratio

Dividend Yield

Current Year

+314 000 USD

Last Year

+233 000 USD

Current Quarter

Last Quarter

+18 000 USD

Current Year

-5 000 USD

Last Year

+65 000 USD

Current Quarter

-83 000 USD

Last Quarter

-83 000 USD

Key Figures ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -121 952 000 USD
Operating Margin TTM -186483.33 %
PE Ratio
Return On Assets TTM -25.52 %
PEG Ratio
Return On Equity TTM -17.21 %
Wall Street Target Price 10.68 USD
Revenue TTM 314 000 USD
Book Value 1.46 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -52.6 %
Dividend Yield
Gross Profit TTM 233 000 USD
Earnings per share -0.21 USD
Diluted Eps TTM -0.21 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY -96.8 %
Profit Margin

Dividend Analytics ATAI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ATAI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 706.1965
Price Sales TTM 1216.114
Enterprise Value EBITDA -6.1068
Price Book MRQ 1.5717

Financials ATAI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATAI

For 52 weeks

1.03 USD 2.85 USD
50 Day MA 1.96 USD
Shares Short Prior Month 6 306 129
200 Day MA 1.62 USD
Short Ratio 3.07
Shares Short 6 106 172
Short Percent 4.94 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics